Ascendis Pharma A/S(NASDAQ:ASND) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $1.126M. Analysts estimated a revenue of $990.000K. The revenues were 13.74% above the estimates. Earnings per share were $-0.55. The reported EPS was above estimates by 8.33%. Analysts had estimated an EPS of $-0.6.
In a different note, On Mar 9, 2017, Leerink Swann said it Downgrades its rating on Ascendis Pharma A/S. According to the research note, Leerink Swann Raises the price target to $30 per share from a prior target of $24. The shares have been rated ‘Market Perform’ by the firm. Credit Suisse said it Initiates Coverage On Ascendis Pharma A/S, according to a research note issued on Feb 9, 2017. In the research note, the firm Announces the price-target to $28 per share. The shares have been rated ‘Outperform’ by the firm.
Ascendis Pharma A/S (ASND) shares turned negative on Fridays trading session with the shares closing down -0.93 points or -3.18% at a volume of 23,025. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $29.58. The peak price level was also seen at $29.58 while the days lowest was $28.03. Finally the shares closed at $28.27. The 52-week high of the shares is $30.57 while the 52-week low is $11.92. According to the latest information available, the market cap of the company is $917 M.
Ascendis Pharma A/S is a clinical stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its lead product candidate TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH the Company has developed a pipeline of long-acting prodrug product candidates such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH) TransCon Insulin for the treatment of diabetes TransCon Peptide for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology.